Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ: ELTX )

6.450 +0.200 (+3.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,016
Open 6.400
Bid (Size) 2.570 (2)
Ask (Size) 9.820 (2)
Prev. Close 6.250
Today's Range 6.200 - 6.450
52wk Range 2.960 - 11.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
+25.49%
+25.49%
1 Month
+28.23%
+28.23%
3 Month
+30.57%
+30.57%
6 Month
+37.82%
+37.82%
1 Year
+55.05%
+55.05%

More News

Read More
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
From Elicio Therapeutics Inc.
Via GlobeNewswire
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Via Benzinga
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
Via News Direct
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Via News Direct
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.